Open discussion

Clinical Cancer Research

Volumn 13, Issue 2 II, 2007, Pages

  Atkins, ^a   Pantuck, ^a   Rini, ^a   Figlin, ^a   Sosman, ^a   Flaherty, ^a   Kaelin, ^a   Wood, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; SORAFENIB; ALPHA INTERFERON; INTERLEUKIN 2; PLACEBO; SUNITINIB;

CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG TARGETING; HUMAN; KIDNEY CANCER; METASTASIS; NEPHRECTOMY; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER PAIN; CANCER REGRESSION; CONFERENCE PAPER; KIDNEY CARCINOMA; POSTOPERATIVE CARE; TREATMENT INDICATION; TUMOR VOLUME;

CARCINOMA, RENAL CELL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY; TREATMENT OUTCOME;

EID: 33846893632     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1916     Document Type: Note

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
4. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005;173:1853-62.
5. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
6. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611-23.
7. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14-7.
8. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6.
9. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9.
10. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70.
11. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978;120:148-52.
12. Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977;117:272-5.
13. Marcus SG, Choyke PL, Reiter R, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993;150:463-6.
14. Walther MM, Patel B, Choyke PL, et al. Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation. J Urol 1997;158:733-9.
15. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
16. Neves RJ, Zincke H, Taylor WF. Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. J Urol 1988;139:1173-6.
17. Bennett RT, Lerner SE, Taub HC, et al. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995;154:32-4.
18. Fallick ML, McDermott DF, LaRock D, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997;158:1691-5.
19. Neves RJ, Zincke H, Taylor WF. Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. J Urol 1988;139:1173-84.
20. Franklin JR, Figlin R, Rauch J, Gitlitz B, Belldegrun A. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin Urol Oncol 1996;14:230-6.
21. Guinan P, Stuhldreher D, Frank W, Rubenstein M. Report of 337 patients with renal cell carcinoma emphasizing 110 with stage IV disease and review of the literature. J Surg Oncol 1997;64:295-8.
22. Citterio G, Di Lucca G, Scaglietti U, Gilberti S, Baldini M, Rugarli C. Reduction of brain metastasis following immunotherapy with interleukin-2 for stage IV renal cell cancer. Acta Oncol 1997;36:228-30.
23. Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997;3:S92-7.
24. Belldegrun A, Shvarts O, Figlin RA. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Cancer J Sci Am 2000;6:S88-92.
25. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003;61:314-9.
26. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 2001;345:1711-2.
27. Wunderlich H, Steiner T, Kosmehl H, et al. Increased transforming growth factor β-1 plasma level in patients with renal cell carcinoma: a tumor-specific marker? Urol Int 1998;60:205-7.
28. Gatenby RA. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res 2002;62:5218-22.
29. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005;23:LBA4510.
30. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;24:16-24.